RxDoctor Payments Data

Kohldon Boydston, MD

Urology · Wauwatosa, WINPI 1518320100

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,918 of the $4,616 with a category attached, or 63.2%. 18 manufacturers reported payments, led by Teleflex LLC at 58.9% of the total. Reporting peaked in 2023 at $2,982 and has fallen 72.9% since, to $808 in 2025.

$4,616in general payments, 2019–2025

Across 63 payments — averaging $73.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$3K
  • Boston Scientific$341
  • Axonics, Inc.$219
  • Coloplast$165
  • Procept Biorobotics Corporation$159
  • Bioprotect Medical, Inc.$155
  • plus $856 from 12 others

What the payments were for

  • Travel & lodging$1,69837%
  • Food & beverage$2,91863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,616 in reported general payments places this provider in the 80th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$89,511
Medicare patients
300
Services billed
1,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron257$181,299
GemtesaVibegron121$78,477
Tamsulosin Hcl457$4,387
Potassium Citrate ErPotassium Citrate52$3,455
Methenamine Hippurate42$2,342
Desmopressin Acetate26$2,131
Finasteride117$1,614
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst79$1,521
NitrofurantoinNitrofurantoin Macrocrystal24$881
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav121$835
Estradiol11$611
Tadalafil16$566
Methenamine Mandelate14$498
Solifenacin Succinate22$485
Doxycycline Monohydrate17$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$150$181,299257 claims
Sumitomo Pharma America, Inc.Gemtesa$59$78,477121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 urology providers in Wisconsin.

Other urology in Wauwatosa

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →